Piper Sandler Reiterates Overweight on Dyne Therapeutics, Maintains $47 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.
Piper Sandler analyst Edward Tenthoff reiterates Dyne Therapeutics (NASDAQ:DYN) with a Overweight and maintains $47 price target.